News of the RadComp Study’s enrollment completion was covered in Penn Medicine News last month. The article, “Patient-powered proton study looks at long-term side effects”, explains the hypotheses of the Study and its potential benefits to the future of breast cancer treatment. It shines a spotlight on the contributions of breast cancer survivors in the Study’s design and execution. “We did this study because we knew this was an important problem that patients cared deeply about,” said Justin Bekelman, MD, the Marietta and Howard Stoeckel Professor at Penn Medicine, who designed and leads the RadComp trial.
For more, read the news story from Penn Medicine.